Immune Checkpoint Inhibitors: all 7,569 studies that test it

Page 45 of 76. Open to participants first (2,567), then studies with results posted, then the rest; newest registration first within each.

• Botensilimab and Balstilimab Optimization in Colorectal CancerActive, not recruitingNCT06268015Phase 2
• A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic CancerCompletedNCT06266143Phase 1/2
• Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma PatientsActive, not recruitingNCT06250335Phase 2
• Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave AblationCompletedNCT06248554Not applicable
• Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal CancerActive, not recruitingNCT06247956Phase 2
• Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWithdrawnNCT06247540Phase 2
• Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT06242834Phase 2
• HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic CholangiocarcinomaActive, not recruitingNCT06239532Phase 2
• A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid TumorStatus unknownNCT06239298Phase 1/2
• Dostarlimab and Cobolimab in Advanced Cervical CancerActive, not recruitingNCT06238635Phase 2
• Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabActive, not recruitingNCT06237920Phase 2
• A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical CancerActive, not recruitingNCT06237257Phase 2
• Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06236438Phase 2/3
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor ThrombosisCompletedNCT06233981Phase 2
• A Study of ZG005 in Patients With Advanced Solid TumorsCompletedNCT06233292Phase 1/2
• A Phase Ⅱ Study of F520 in Patients With Cervical CarcinomaCompletedNCT06226350Phase 2
• Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLCActive, not recruitingNCT06219317Phase 2
• A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)Active, not recruitingNCT06218511Phase 1
• Neoadjuvant Immunotherapy for T4 dMMR Colon CancerActive, not recruitingNCT06215677Phase 2
• Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.Active, not recruitingNCT06195683Phase 2
• --SuPERIOR Trial--TerminatedNCT06191250Phase 2
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaActive, not recruitingNCT06190951Phase 2
• Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell LymphomaActive, not recruitingNCT06188676Phase 3
• Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine CancerActive, not recruitingNCT06180733Phase 2
• Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract CancerActive, not recruitingNCT06178445Phase 2
• Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCTerminatedNCT06173505Phase 1/2
• SG2918 For Advanced Malignant TumorsCompletedNCT06167486Phase 1
• Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin LymphomaActive, not recruitingNCT06164275Phase 2
• Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06162572Phase 1/2
• A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryActive, not recruitingNCT06161441Phase 2
• A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)CompletedNCT06159790Phase 3
• T Cells and Pembrolizumab for Recurrent and Newly Diagnosed GlioblastomaActive, not recruitingNCT06157541Phase 1/2
• Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)Active, not recruitingNCT06155279Phase 2
• A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III MelanomaCompletedNCT06153238Phase 1
• Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)Active, not recruitingNCT06143748Phase 2
• Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung CancerTerminatedNCT06140407Phase 2
• Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors PatientsCompletedNCT06139536Phase 1
• PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder CancerActive, not recruitingNCT06133517Phase 2
• Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO TrialActive, not recruitingNCT06128863Phase 2
• A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)Active, not recruitingNCT06127043Phase 2
• Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon CancerActive, not recruitingNCT06124378Phase 2
• A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung CancerActive, not recruitingNCT06116786Phase 1
• Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant PembrolizumabWithdrawnNCT06116578Phase 2
• A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid TumorsActive, not recruitingNCT06116240Phase 1
• Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)TerminatedNCT06114940Phase 2
• A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06112808Phase 1
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerActive, not recruitingNCT06112379Phase 3
• Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)Active, not recruitingNCT06109779Phase 3
• Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerActive, not recruitingNCT06109467Phase 2
• A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingNCT06109272Phase 2/3
• Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical TrailCompletedNCT06108596Phase 2
• Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast CancerWithdrawnNCT06105008Phase 2
• KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadeActive, not recruitingNCT06099821Phase 2
• MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaActive, not recruitingNCT06097728Phase 3
• A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisActive, not recruitingNCT06096779Phase 2
• NEO-adjuvant Chemo-immunotherapy in Pancreatic CancerActive, not recruitingNCT06094140Phase 2
• Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT06091943Phase 1
• Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A LossWithdrawnNCT06090318Phase 1/2
• Ketohexokinase Inhibition in Hereditary Fructose IntoleranceCompletedNCT06089265Phase 2
• Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresWithdrawnNCT06084689Phase 2
• Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT06083454Phase 1
• Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCCActive, not recruitingNCT06081673Phase 2
• The Seven Trial: Exploiting the Unfolded Protein ResponseTerminatedNCT06076837Phase 1
• Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid TumorsCompletedNCT06076135Phase 2
• Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC ImmunotherapyActive, not recruitingNCT06074029Phase 1/2
• "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast CancerTerminatedNCT06067061Phase 1/2
• A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202Active, not recruitingNCT06062420Phase 2
• Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCCStatus unknownNCT06059885Phase 2
• Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell CarcinomaActive, not recruitingNCT06056895Phase 2
• Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06055816Phase 2
• Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung CancerActive, not recruitingNCT06055465Phase 2
• A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic MelanomaActive, not recruitingNCT06054555Phase 3
• Study of ALE.C04 in Patients With Head and Neck CancerTerminatedNCT06054477Phase 1/2
• A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)WithdrawnNCT06050954Phase 2
• Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before SurgerySuspendedNCT06050252Phase 2
• Atezolizumab in Large Cell Neuroendocrine CarcinomaCompletedNCT06049966Phase 1
• Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Active, not recruitingNCT06048133Phase 2
• GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial CancerWithdrawnNCT06046274Phase 2
• A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)Active, not recruitingNCT06041802Phase 2
• A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)Active, not recruitingNCT06041269Phase 2
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREActive, not recruitingNCT06040099Phase 2
• Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)CompletedNCT06036836Phase 2
• A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382TerminatedNCT06032546Phase 2
• Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06027268Phase 2
• Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell CarcinomaStatus unknownNCT06023875Phase 2
• Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal TumoursCompletedNCT06022692Phase 1/2
• The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant TumorActive, not recruitingNCT06022250Phase 1
• Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract InfectionsCompletedNCT06020001Not applicable
• Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic CholangiocarcinomaWithdrawnNCT06017297Phase 2
• A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Phase 2
• Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)Active, not recruitingNCT06009861Phase 2
• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASActive, not recruitingNCT06008093Phase 2
• A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular CarcinomaWithdrawnNCT06006286Phase 1/2
• Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) NegativeActive, not recruitingNCT06001151Phase 2
• Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal CancerActive, not recruitingNCT05999812Phase 2
• Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced MelanomaActive, not recruitingNCT05986331Phase 3
• A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic CancerActive, not recruitingNCT05984602Phase 1
• A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Active, not recruitingNCT05984277Phase 3
• TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT05980598Phase 2
• A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).TerminatedNCT05975645Phase 1

← Immune Checkpoint Inhibitors overview